<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680834</url>
  </required_header>
  <id_info>
    <org_study_id>6010</org_study_id>
    <nct_id>NCT02680834</nct_id>
  </id_info>
  <brief_title>VLU Non-Inferiority Study Comparing a Dual Action Pneumatic Compression Device to Multi-Layer Bandaging</brief_title>
  <official_title>Randomized Trial Comparing a Dual Action Pneumatic Compression System Against Multi-Layer Bandaging Systems: A Non-Inferiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tactile Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tactile Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test non-inferiority of chronic Venous Leg Ulcer (VLU) area
      reduction at 16 weeks with a dual action pneumatic compression device compared to multi-layer
      bandaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with a chronic venous leg ulcer will participate in a 2 week run in phase using
      standard of care multi-layer bandaging before being randomly assigned to either treatment
      using a dual action pneumatic compression device or continued multi-layer bandaging for up to
      16 weeks. Participants will be seen in clinic for treatment and evaluation of symptoms and
      quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The ACT was re-designed per physician feedback and patient compliance &amp; not because of safety.
  </why_stopped>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of VLU Area Reduction</measure>
    <time_frame>Changes from Baseline to 16 weeks</time_frame>
    <description>Percentage of ulcer area reduction in the target VLU during the 16 week treatment period calculated by wound imaging software.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Quality of Life</measure>
    <time_frame>Changes from Baseline to 16 weeks</time_frame>
    <description>The Charing Cross Venous Ulcer Questionnaire assesses the patients' perception of their health when venous ulceration is present. All items are scored so that a lower score defines a more favorable health state (a greater reduction is associated with improved quality of life). In addition, each item is scored using a 1 to 5 range so that the lowest and highest possible scores are 0 and 100, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outpatient Costs</measure>
    <time_frame>Changes from Baseline to 16 weeks</time_frame>
    <description>Assessment of the effect of the Actitouch compared to a standard regimen of multi-layer bandaging on mean total outpatient costs per subject.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>Dual Action Pneumatic Compression Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-layer bandaging</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dual Action Pneumatic Compression Device</intervention_name>
    <description>Dual action pneumatic compression device used to treat chronic VLUs.</description>
    <arm_group_label>Dual Action Pneumatic Compression Device</arm_group_label>
    <other_name>ACTitouch system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multi-Layer Bandaging</intervention_name>
    <description>Multi-layer bandaging used to treated chronic VLUs</description>
    <arm_group_label>Multi-layer bandaging</arm_group_label>
    <other_name>Profore or Coban 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be ≥ 18 years of age or legal age at the time of enrollment.

          -  Chronic venous insufficiency confirmed by ultrasound within previous 12 months or
             prior to randomization: if subject had bilateral CVI, the limb that possessed the
             largest ulcer meeting study criteria was used as the study treatment limb for
             evaluation and documentation throughout the study. Non-study limbs received standard
             of care treatment as determined by the treating clinician.

          -  Must have at least one of the following within the past six (6) months: Dorsalis Pedis
             (DP) systolic pressure ≥ 80mmHg for diabetic patients or ≥ 60mmHg for non-diabetic
             patients on study limb; Posterior Tibial (PT) systolic pressure ≥ 80mmHg for diabetic
             patients or ≥ 60mmHg for non-diabetic patients on study limb; Transcutaneous partial
             pressure oxygen (TcP02) &gt; 30mmHg; Great toe systolic pressure &gt; 40mmHg.

          -  Active ulceration (CEAP classification of C6): VLU was defined by open skin lesion of
             the leg or foot that occurred in an area affected by venous hypertension.

          -  Ulcer duration: Non healing VLU ≥ 1 month but not greater than 24 months.

          -  Ulcer size ≥ 2cm² ≤ 50cm²: if there were multiple ulcers on the study limb, the
             largest ulcer was used as the study treatment ulcer for evaluation and documentation
             throughout the study. If two ulcers were separated by no more than one centimeter of
             normal skin, their areas were added together for study purposes.

          -  Three or fewer separate full thickness ulcers on the study limb: sum of the ulcer
             areas on the study limb must be ≤ 50 cm².

          -  Leg circumferences within the following range: Ankle - 12 to 44cm; Calf - 22 to 60cm;
             Below knee - 22 to 68cm.

          -  Able and willing to provide informed consent prior to study participation.

        Exclusion Criteria:

          -  Target ulcer or any other ulcer on the study limb involves exposure of tendon, muscle,
             or bone.

          -  Target ulcer was of non-venous etiology (sickle cell anemia, necrobiosis lipoidica
             diabeticorum, pyoderma, malignancy).

          -  Treatment of the target ulcer with living cellular therapy within 30 days of the time
             of projected randomization.

          -  Endovenous ablation or other venous surgery within two weeks of enrollment: venous
             ultrasound must be completed after procedure to determine whether there is still
             venous insufficiency at the time of enrollment.

          -  History of skin sensitivity to any of the components of ACT, multi-layer bandages of
             compression garments.

          -  History of an acute deep vein thrombosis (DVT) or pulmonary embolism (PE) within the
             last three (3) months.

          -  Acute thrombophlebitis within the last six (6) weeks.

          -  History of pulmonary edema or decompensated congestive heart failure within six (6)
             weeks of screening.

          -  Currently has an active infection of the skin on the target limb such as cellulitis
             requiring antibiotics.

          -  History of target limb cancer within the last 2 years with the exception of treated
             non-melanoma skin cancer unless ulcer biopsy performed at screening is negative for
             neoplasia.

          -  Active cancer receiving chemotherapy and/or radiation therapy.

          -  Poorly controlled diabetes with an HbA1c value of &gt; 12% within the past three (3)
             months.

          -  Changes to medications that affected edema within the last 30 days prior to enrollment
             (e.g., diuretics, calcium channel blockers of the dihyropyridine class, pioglitazone,
             cox-1 inhibitors, pregabalin, and gabapentin, diltiazem, or fluctuating doses of
             systemic steroids).

          -  Use of systemic corticosteroids requiring daily administration at doses greater than
             5mg of Prednisone per day or equivalent for greater than 2 weeks: low dose steroid
             administration (Prednisone up to 5 mg per day or equivalent) was allowable for an
             unlimited period of time. Topical steroid administration to peri-ulcer area or other
             skin was allowable but could not be applied to the ulcer itself.

          -  Currently pregnant or trying to become pregnant.

          -  Inability or unwillingness to participate in all aspects of study protocol.

          -  Exhibited any condition which, according to the Investigator, justified the subject's
             exclusion from the study, such as a medical condition where an increase in venous or
             lymphatic return is undesirable.

          -  Currently participating in another clinical trial.

        Additional Exclusion Criteria after two week run-in:

          -  Subject's target ulcer decreased in size by greater than 30% compared to the baseline
             area.

          -  Subject's target ulcer increased in size by greater than 50% compared to the baseline
             area.

          -  Subject's target ulcer measured less than 1.5cm² at the Randomization Visit.

          -  Subject appeared to have evidence of infection in any ulcer.

          -  The sum of the ulcer areas on the subject's study limb is &gt; 50cm².
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Marston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix VA Health Care System</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Foot and Ankle Specialists, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Regional Medical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ILD Research Center</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limb Preservation Platform - Northwest</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limb Preservation Platform - Downtown</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach VA Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Los Angeles VA Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olive View - UCLA Medical Center</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barry University Clinical Research</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Institute of South Florida</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jobst Vascular Institute</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2016</study_first_posted>
  <results_first_submitted>December 28, 2019</results_first_submitted>
  <results_first_submitted_qc>January 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2020</results_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>venous stasis ulcer</keyword>
  <keyword>wound</keyword>
  <keyword>chronic venous insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02680834/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02680834/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All subjects participated in a two week run-in phase. The treatment included MLB which was worn 24 hours a day except during clinic visits. The run-in phase was intended to assess the subject’s initial response to standard of care treatment using MLB before receiving treatment with the investigational device.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dual Action Pneumatic Compression Device</title>
          <description>ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
Dual Action Pneumatic Compression Device: Dual action pneumatic compression device used to treat chronic VLUs.</description>
        </group>
        <group group_id="P2">
          <title>Multi-layer Bandaging</title>
          <description>PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
Multi-Layer Bandaging: Multi-layer bandaging used to treated chronic VLUs</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dual Action Pneumatic Compression Device</title>
          <description>ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
Dual Action Pneumatic Compression Device: Dual action pneumatic compression device used to treat chronic VLUs.</description>
        </group>
        <group group_id="B2">
          <title>Multi-layer Bandaging</title>
          <description>PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
Multi-Layer Bandaging: Multi-layer bandaging used to treated chronic VLUs</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="10"/>
                    <measurement group_id="B2" value="64" spread="10"/>
                    <measurement group_id="B3" value="64" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of VLU Area Reduction</title>
        <description>Percentage of ulcer area reduction in the target VLU during the 16 week treatment period calculated by wound imaging software.</description>
        <time_frame>Changes from Baseline to 16 weeks</time_frame>
        <population>*Per Protocol Population (MITT patients who were randomized, received treatment, and did not exit the study early).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Action Pneumatic Compression Device</title>
            <description>ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
Dual Action Pneumatic Compression Device: Dual action pneumatic compression device used to treat chronic VLUs.</description>
          </group>
          <group group_id="O2">
            <title>Multi-layer Bandaging</title>
            <description>PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
Multi-Layer Bandaging: Multi-layer bandaging used to treated chronic VLUs</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of VLU Area Reduction</title>
          <description>Percentage of ulcer area reduction in the target VLU during the 16 week treatment period calculated by wound imaging software.</description>
          <population>*Per Protocol Population (MITT patients who were randomized, received treatment, and did not exit the study early).</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.8" spread="27.8"/>
                    <measurement group_id="O2" value="-70.5" spread="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-Reported Quality of Life</title>
        <description>The Charing Cross Venous Ulcer Questionnaire assesses the patients' perception of their health when venous ulceration is present. All items are scored so that a lower score defines a more favorable health state (a greater reduction is associated with improved quality of life). In addition, each item is scored using a 1 to 5 range so that the lowest and highest possible scores are 0 and 100, respectively.</description>
        <time_frame>Changes from Baseline to 16 weeks</time_frame>
        <population>Per Protocol Population (Patients randomized who received treatment and had both Baseline and end of study measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Action Pneumatic Compression Device</title>
            <description>ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
Dual Action Pneumatic Compression Device: Dual action pneumatic compression device used to treat chronic VLUs.</description>
          </group>
          <group group_id="O2">
            <title>Multi-layer Bandaging</title>
            <description>PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
Multi-Layer Bandaging: Multi-layer bandaging used to treated chronic VLUs</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-Reported Quality of Life</title>
          <description>The Charing Cross Venous Ulcer Questionnaire assesses the patients' perception of their health when venous ulceration is present. All items are scored so that a lower score defines a more favorable health state (a greater reduction is associated with improved quality of life). In addition, each item is scored using a 1 to 5 range so that the lowest and highest possible scores are 0 and 100, respectively.</description>
          <population>Per Protocol Population (Patients randomized who received treatment and had both Baseline and end of study measures).</population>
          <units>Change in total score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="15.4"/>
                    <measurement group_id="O2" value="-1.7" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outpatient Costs</title>
        <description>Assessment of the effect of the Actitouch compared to a standard regimen of multi-layer bandaging on mean total outpatient costs per subject.</description>
        <time_frame>Changes from Baseline to 16 weeks</time_frame>
        <population>Per Protocol Population (Patients randomized who received treatment and had baseline and end of study measures).</population>
        <group_list>
          <group group_id="O1">
            <title>Dual Action Pneumatic Compression Device</title>
            <description>ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
Dual Action Pneumatic Compression Device: Dual action pneumatic compression device used to treat chronic VLUs.</description>
          </group>
          <group group_id="O2">
            <title>Multi-layer Bandaging</title>
            <description>PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
Multi-Layer Bandaging: Multi-layer bandaging used to treated chronic VLUs</description>
          </group>
        </group_list>
        <measure>
          <title>Outpatient Costs</title>
          <description>Assessment of the effect of the Actitouch compared to a standard regimen of multi-layer bandaging on mean total outpatient costs per subject.</description>
          <population>Per Protocol Population (Patients randomized who received treatment and had baseline and end of study measures).</population>
          <units>Dollars</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6748" spread="1308"/>
                    <measurement group_id="O2" value="8925" spread="2176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 Weeks</time_frame>
      <desc>An adverse event (AEs) includes any complication whose clinical significance is greater than anticipated, or which occurs with a frequency greater than that which is usually seen for this type of device.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dual Action Pneumatic Compression Device</title>
          <description>ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
Dual Action Pneumatic Compression Device: Dual action pneumatic compression device used to treat chronic VLUs.</description>
        </group>
        <group group_id="E2">
          <title>Multi-layer Bandaging</title>
          <description>PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
Multi-Layer Bandaging: Multi-layer bandaging used to treated chronic VLUs</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar stenosis; spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain/Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After the multi-center publication, or if no multi-center publication is submitted for publication within 12 months after the conclusion or termination of the study at all sites, site may publish on your own site’s data only. A draft of the manuscript must be submitted to Sponsor for review at least 45 days prior to submission for publication and 15 days for oral presentation. Sponsor shall respond to institution within 45 days of the receipt of draft.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination led to small numbers of subjects analyzed. Study was terminated early so the device could undergo a complete re-design to address physician feedback collected during the trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Research Director</name_or_title>
      <organization>TactileMedical</organization>
      <phone>612-540-5267</phone>
      <email>astone@tactilemedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

